MIRM · Mirum Pharmaceuticals, Inc.
$79.96
+0.34 (+0.43%)
At close · Oct 14
Return incl. dividend (before tax)
Market Cap
$5.17B
Shares
64.93M
Volume · Oct 14
975.15K
Avg daily vol (3M)
719.49K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$79.96
Open$78.41
Day$78.35–81.91
52W close$64.10–128.57
Avg vol 30d826K
Short int7.0M · 10.8% float · 7.7d
Short vol23%
Last earningsAug 5, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 3 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$618.07M
Trailing 12 months
Net income (TTM)
−$860.21M
Trailing 12 months
Revenue growth YoY
+37.9%
Year over year
Operating margin
-134.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-4.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$438.29M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+27.4%
Year over year · more shares
Price change (1Y)
+10.3%
Trailing year
Short interest
10.8%
Latest settlement · 7.7 days to cover
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.54
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
−15%
below
RSI (14)
33
neutral
MACD trend
Positive
52-week position
25%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−18%
trailing
6-month return
−13%
trailing
YTD return
+1%
this year
Relative strength
−22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $94 › 200d $98 — 200d above 50d
Institutional flow
Distributing
13 of 330 funds reported for Sep 30 · net -10.0K sh shares · +1 new
Insider flow
Distributing
Net -$5.0M over 90 days · 100% sells
Short interest
Rising
10.76% of float · ▲ +11.2% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
330 holders — near 3-yr high, broad support
Squeeze score
73
high risk · 0–100
Fundamentals
EPS growth
+75%
Y/Y
Free cash flow
$54.9M
Quant / Vol
risk profile
Volatility
47%
annualized · 1-yr
Max drawdown
−38%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Net product sales
· full year 2026
Raised
$680M – $700M
May 6, 2026
$660M – $680M
changed to
Aug 5, 2026
$680M – $700M
prior FY $521.31M
midpoint +32.4% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
33
Neutral
MACD trend
Positive
Bullish
52-week position
25%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $94 › 200d $98 — 200d above 50d
Institutional flow
Distributing
13 of 330 funds reported for Sep 30 · net -10.0K sh shares · +1 new
Insider flow
Distributing
Net -$5.0M over 90 days · 100% sells
Short interest
Rising
10.76% of float · ▲ +11.2% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
330 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $64
Now $80 · 25%
Range high $129
vs 200-day avg -19%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Bile Acid Medicines net product sales | $47.5M | Q2 2026 | +19.9% |
|
|
|||
| Global net product sales | $176.2M | Q2 2026 | +37.9% |
|
|
|||
| LIVMARLI net product sales | $128.7M | Q2 2026 | +46.0% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MIRM
this stock
Mirum Pharmaceuticals, Inc.
|
$5.17B | +1.2% | +54.7% | — | 10.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.98B | +10.0% | +46.2% | 28.3 | 1.8% |
|
MRNA
Moderna, Inc.
|
$86.33B | +667.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$77.54B | +0.8% | +20.8% | 18.7 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.81B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MIRM | -0.8% | -17.9% | -13.0% | -6.5% | +1.2% |
| SPY | -1.0% | +2.1% | +8.6% | +0.9% | +12.9% |
| vs SPY | +0.1% | -19.9% | -21.7% | -7.4% | -11.6% |
Key facts
CIK
1759425
CUSIP
604749101
13F (30d)
17 filings
16 filers
Visit website
Investor relations